CompBrief BY VELARION

Companies Provention Bio, Inc.

Provention Bio CEO salary & total pay, FY2022: $2.3M

Provention Bio (PRVB) CEO salary, fiscal 2022: Ashleigh Palmer was paid a salary of $675,000 and $2,266,108 in total compensation. Free brief. Every figure links to the company’s own filing.

Provention Bio, Inc. no longer files a proxy statement; its last pay data is FY2022.

All products and prices

Ashleigh Palmer's complete compensation dossier

A PDF and a CSV sent to your email: Ashleigh Palmer's pay in every fiscal year Provention Bio, Inc. reported it, line by line, with Ashleigh Palmer's equity grants and Provention Bio, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$2,266,108CEO Ashleigh Palmer · source
Say-on-pay support95.23%Latest vote · source

CEO pay, last three years

  • $1,566,779FY2021
  • $2,266,108FY2022

CEO total pay was $2,266,108 in fiscal 2022, up from $1,566,779 in fiscal 2021.

FY2022: salary $675,000 · bonus $0 · stock awards $0 · option awards $1,092,908

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Provention Bio, Inc. in fiscal 2022?
As disclosed, Ashleigh Palmer (Chief Executive Officer) was the highest-paid executive at Provention Bio, Inc. in fiscal 2022, with total compensation of $2,266,108.
How did shareholders vote on Provention Bio, Inc.'s executive compensation?
As disclosed, 95.23% of shareholders supported Provention Bio, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Provention Bio, Inc. spend in total on board compensation for fiscal 2022?
As disclosed, Provention Bio, Inc. reported total board compensation of $336,385 for fiscal 2022.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Ashleigh Palmer$675,000$0$0$1,092,908$486,000$0$12,200$2,266,108
Chief Executive Officer
Eleanor Ramos475,00000442,471228,000012,2001,157,671
Chief Medical Officer
Francisco Leon475,00000442,471228,000012,2001,157,671
Chief Scientific Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2022 totalFY2021 totalFY2020 totalΔ FY2021→2022
Ashleigh Palmer$2,266,108$1,566,779—↑ +699,329
Eleanor Ramos1,157,6711,278,198—↓ −120,527
Francisco Leon1,157,6711,276,424—↓ −118,753

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company's executive compensation program is designed to closely tie pay to performance, rewarding executives for the achievement of corporate short-term and longer-term strategic goals that create stockholder value. The program is heavily reliant on variable, 'at-risk' pay, with the majority of compensation provided in the form of variable incentives to align management interests with stockholders.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2022

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Ashleigh PalmerOption360,00040,00012.54—
Ashleigh PalmerOption48,21327,55012.62—
Ashleigh PalmerOption48,21361,98712.62—
Ashleigh PalmerOption27,60942,1416.8—
Ashleigh PalmerOption27,60969,7506.8—
Ashleigh PalmerOption—360,0004.37—
Ashleigh PalmerOption541,720—2.5—
Eleanor RamosOption360,00040,00012.54—
Eleanor RamosOption48,21327,55012.62—
Eleanor RamosOption48,21361,98712.62—
Eleanor RamosOption27,60942,1416.8—
Eleanor RamosOption27,60969,7506.8—
Eleanor RamosOption—145,0004.39—
Eleanor RamosOption460,462—2.5—
Francisco LeonOption360,00040,00012.54—
Francisco LeonOption48,21327,55012.62—
Francisco LeonOption48,21361,98712.62—
Francisco LeonOption27,60942,1416.8—
Francisco LeonOption27,60969,7506.8—
Francisco LeonOption—145,0004.39—
Francisco LeonOption342,103—2.5—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Sean DohertyIndependent · Departed during FY$46,033—$393,796——$439,829
Wayne PisanoIndependent97,823—100,540——198,363
Avery CatlinIndependent67,500—100,540——168,040
Nancy WysenskiIndependent58,539—100,540——159,079
John JenkinsIndependent49,677—100,540——150,217
Jeffery BluestoneIndependent · Departed during FY16,813—100,540——117,353

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2022
Cash retainers and fees$336,385
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$336,385

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Provention Bio as a peer

Companies that benchmark against PRVB

No companies currently name PRVB as a compensation peer in their most recent disclosure.

This is the complete answer, not a partial one — the list is never padded.

Disclosed peer group — fiscal year 2022

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Rhythm Pharmaceuticals, Inc.2025David Meeker$807,692$8,274,785$7,688,560$759,488$17,544,525
2Kiniksa Pharmaceuticals, Ltd.2025Sanj Patel943,1293,798,0214,743,4461,284,06510,782,661
3Geron Corporation2025Harout Semerjian321,53809,695,400203,00010,221,755
4Syndax Pharmaceuticals, Inc.2025Michael Metzger754,3002,021,9653,454,360848,5887,089,213
5Rigel Pharmaceuticals, Inc.2025Raul Rodriguez787,405951,3272,241,570634,6494,658,805
6Selecta Biosciences Inc.2025Carsten Brunn674,000973,4752,314,320363,9604,329,868
7Puma Biotechnology, Inc.2025Alan Auerbach931,333551,549535,5131,027,3073,062,337
8Provention Bio, Inc.2022Ashleigh Palmer675,00001,092,908486,0002,266,108
9CytoDyn Inc.2026Jacob Lalezari409,89601,208,18401,833,398
10Chimerix Inc.2023Mike Sherman514,695183,112778,51101,517,854
11Atara Biotherapeutics, Inc.2025AnhCo Nguyen668,8000001,068,069
12VBI Vaccines Inc.2023Jeffrey Baxter697,9280121,7360893,546
13BeyondSpring Inc.2025Lan Huang452,920037,522201,323702,182
—BioXcel Therapeutics, Inc.——————not in coverage universe
—Zogenix, Inc.——————not in coverage universe
—CymaBay Therapeutics, Inc.——————not in coverage universe
—Spectrum Pharmaceuticals, Inc.——————not in coverage universe
—Xoma Corporation——————not in coverage universe
—Athersys, Inc.——————not in coverage universe
—Tricida, Inc.——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Provention Bio, Inc.not disclosedOption 100not disclosedAon
Atara Biotherapeutics, Inc.not disclosedRSU 100not disclosedPearl Meyer
Athersys, Inc.not disclosednot disclosednot disclosednot disclosed
BeyondSpring Inc.not disclosedOption 100not disclosednot disclosed
BioXcel Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Chimerix Inc.85%Option 86 · RSU 14not disclosedAon
CymaBay Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
CytoDyn Inc.not disclosednot disclosednot disclosedAon
Geron Corporation90%Options 75 · RSU 25not disclosedAon
Kiniksa Pharmaceuticals, Ltd.not disclosedOption 50 · RSU 25 · PSU 25not disclosedCompensia, Inc.
Puma Biotechnology, Inc.169.7%Options 50 · RSU 50not disclosedCompensia
Rhythm Pharmaceuticals, Inc.120%Options 50 · RSU 50NoPay Governance
Rigel Pharmaceuticals, Inc.124%Options 75 · RSU 25NoPearl Meyer
Selecta Biosciences Inc.not disclosednot disclosednot disclosedCompensia
Spectrum Pharmaceuticals, Inc.not disclosednot disclosednot disclosednot disclosed
Syndax Pharmaceuticals, Inc.150%Options 34 · PSU 33 · RSU 33Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRsAon
Tricida, Inc.not disclosednot disclosednot disclosednot disclosed
VBI Vaccines Inc.not disclosedOption 100not disclosednot disclosed
Xoma Corporationnot disclosednot disclosednot disclosednot disclosed
Zogenix, Inc.not disclosednot disclosednot disclosednot disclosed

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20222022-05-1726,392,5871,137,164185,99595.23%Passed
20212021-05-1226,478,3641,138,224194,08795.21%Passed
20202020-07-15—————
20192019-05-29—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20222022-05-1795.23%a
20212021-05-1295.21%b
20202020-07-15—c

a. Approved under the standard stated in the filing — “Proposal 2: With respect to the second proposal (executive compensation), the affirmative vote of a majority of the voting power of the shares present in person (including virtually) or represented by proxy and entitled to vote thereon is required to approve the proposal.”.

b. Approved under the standard stated in the filing — “Proposal 2: With respect to the second proposal (executive compensation), the affirmative vote of a majority of the voting power of the shares present in person (including virtually) or represented by proxy and entitled to vote thereon is required to approve the proposal.”.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

No insider equity transactions reported since the proxy statement.

Sources (27 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Ashleigh Palmer. 10-K, filed 2023-03-29. Section “Executive Compensation” · page 127. As printed: 2,266,108. View filing ↗
  • Section 01, Eleanor Ramos. 10-K, filed 2023-03-29. Section “Executive Compensation” · page 127. As printed: 1,157,671. View filing ↗
  • Section 01, Francisco Leon. 10-K, filed 2023-03-29. Section “Executive Compensation” · page 127. As printed: 1,157,671. View filing ↗
  • Section 08, Sean Doherty. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 439,829. View filing ↗
  • Section 08, Wayne Pisano. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 198,363. View filing ↗
  • Section 08, Avery Catlin. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 168,040. View filing ↗
  • Section 08, Nancy Wysenski. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 159,079. View filing ↗
  • Section 08, John Jenkins. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 150,217. View filing ↗
  • Section 08, Jeffery Bluestone. 10-K, filed 2023-03-29. Section “Director Compensation”. As printed: 117,353. View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-05-20. Item 5.07 · say-on-pay result. As reported: 95.23% (votes for as printed: 26,392,587). View filing ↗
  • Section 06, 2021 vote. Form 8-K, filed 2021-05-14. Item 5.07 · say-on-pay result. As reported: 95.21% (votes for as printed: 26,478,364). View filing ↗
  • Section 06, 2020 vote. Form 8-K, filed 2020-07-16. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 336,385 + equity 0 + all other 0 = 336,385, summed across the director compensation table rows.
  • Rhythm Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Rhythm Pharmaceuticals, Inc.'s own proxy. As printed: 17,544,525. View filing ↗
  • Kiniksa Pharmaceuticals, Ltd., Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Kiniksa Pharmaceuticals, Ltd.'s own proxy. As printed: 10,782,661. View filing ↗
  • Geron Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Geron Corporation's own proxy. As printed: 10,221,755. View filing ↗
  • Syndax Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals, Inc.'s own proxy. As printed: 7,089,213. View filing ↗
  • Rigel Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Rigel Pharmaceuticals, Inc.'s own proxy. As printed: 4,658,805. View filing ↗
  • Selecta Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Selecta Biosciences Inc.'s own proxy. As printed: 4,329,868. View filing ↗
  • Puma Biotechnology, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Puma Biotechnology, Inc.'s own proxy. As printed: 3,062,337. View filing ↗
  • Provention Bio, Inc. (subject), Section 10b CEO total. 10-K, filed 2023-03-29. CEO total compensation as printed in Provention Bio, Inc.'s own proxy. As printed: 2,266,108. View filing ↗
  • CytoDyn Inc., Section 10b CEO total. DEF 14A, filed 2026-09-28. CEO total compensation as printed in CytoDyn Inc.'s own proxy. As printed: 1,833,398. View filing ↗
  • Chimerix Inc., Section 10b CEO total. DEF 14A, filed 2024-04-26. CEO total compensation as printed in Chimerix Inc.'s own proxy. As printed: 1,517,854. View filing ↗
  • Atara Biotherapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Atara Biotherapeutics, Inc.'s own proxy. As printed: 1,068,069. View filing ↗
  • VBI Vaccines Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in VBI Vaccines Inc.'s own proxy. As printed: 893,546. View filing ↗
  • BeyondSpring Inc., Section 10b CEO total. 10-K, filed 2026-03-25. CEO total compensation as printed in BeyondSpring Inc.'s own proxy. As printed: 702,182. View filing ↗